Selected research
Market Structure
Global Nuclear Drug for Therapeutic Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Nuclear Drug for Therapeutic market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Nuclear Drug for Therapeutic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Nuclear Drug for Therapeutic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Nuclear Drug for Therapeutic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Nuclear Drug for Therapeutic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Nuclear Drug for Therapeutic include Aurobindo Pharma, China Isotope & Radiation, Curium Pharmaceuticals, Dongcheng, International Isotopes, Jubilant Radiopharma, Lantheus, Mundipharma and Q BioMed, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Nuclear Drug for Therapeutic market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Nuclear Drug for Therapeutic and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Nuclear Drug for Therapeutic revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Nuclear Drug for Therapeutic market size, projected growth trends, production technologies, key applications, and end-use industries.
Nuclear Drug for Therapeutic Segment by Company
Aurobindo Pharma
China Isotope & Radiation
Curium Pharmaceuticals
Dongcheng
International Isotopes
Jubilant Radiopharma
Lantheus
Mundipharma
Q BioMed
Bayer
Novartis
Nuclear Drug for Therapeutic Segment by Type
Iodine-131
Radium-223
Lutetium-177
Other
Nuclear Drug for Therapeutic Segment by Application
Lymphoma
Thyroid
Bone Metastasis
Other
Nuclear Drug for Therapeutic Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nuclear Drug for Therapeutic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nuclear Drug for Therapeutic and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nuclear Drug for Therapeutic.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Nuclear Drug for Therapeutic in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Nuclear Drug for Therapeutic industry.
Chapter 3: Detailed analysis of Nuclear Drug for Therapeutic companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nuclear Drug for Therapeuticrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Iodine-131
- Radium-223
- Lutetium-177
- Other
Applications
- Lymphoma
- Thyroid
- Bone Metastasis
- Other
Companies covered
- Aurobindo Pharma
- China Isotope & Radiation
- Curium Pharmaceuticals
- Dongcheng
- International Isotopes
- Jubilant Radiopharma
- Lantheus
- Mundipharma
- Q BioMed
- Bayer
- Novartis
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Nuclear Drug for Therapeutic Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Iodine-131
- 1.2.3 Radium-223
- 1.2.4 Lutetium-177
- 1.2.5 Other
- 1.3 Market Analysis by Application
- 1.3.1 Global Nuclear Drug for Therapeutic Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Lymphoma
- 1.3.3 Thyroid
- 1.3.4 Bone Metastasis
- 1.3.5 Other
- 1.4 Global Market Growth Prospects
- 1.5 Global Nuclear Drug for Therapeutic Growth Trends by Region
- 1.5.1 Global Nuclear Drug for Therapeutic Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Nuclear Drug for Therapeutic Market Size by Region (2021-2026)
- 1.5.3 Nuclear Drug for Therapeutic Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Nuclear Drug for Therapeutic Market Dynamics
- 2.1 Nuclear Drug for Therapeutic Industry Trends
- 2.2 Nuclear Drug for Therapeutic Industry Drivers
- 2.3 Nuclear Drug for Therapeutic Industry Opportunities and Challenges
- 2.4 Nuclear Drug for Therapeutic Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Nuclear Drug for Therapeutic Revenue by Company (2021-2026)
- 3.2 Global Nuclear Drug for Therapeutic Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Nuclear Drug for Therapeutic Key Company Head office and Area Served
- 3.4 Global Nuclear Drug for Therapeutic Company, Product Type & Application
- 3.5 Global Nuclear Drug for Therapeutic Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Nuclear Drug for Therapeutic Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Nuclear Drug for Therapeutic Players Market Share by Revenue in 2025
- 3.6.3 2025 Nuclear Drug for Therapeutic Tier 1, Tier 2, and Tier 3
4 Nuclear Drug for Therapeutic Market by Type
- 4.1 Global Nuclear Drug for Therapeutic Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Nuclear Drug for Therapeutic Market Size by Type (2021-2032)
- 4.3 Global Nuclear Drug for Therapeutic Market Size Share by Type (2021-2032)
5 Nuclear Drug for Therapeutic Market by Application
- 5.1 Global Nuclear Drug for Therapeutic Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Nuclear Drug for Therapeutic Market Size by Application (2021-2032)
- 5.3 Global Nuclear Drug for Therapeutic Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Aurobindo Pharma
- 6.1.1 Aurobindo Pharma Company Information
- 6.1.2 Aurobindo Pharma Business Overview
- 6.1.3 Aurobindo Pharma Nuclear Drug for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Aurobindo Pharma Nuclear Drug for Therapeutic Product Portfolio
- 6.1.5 Aurobindo Pharma Recent Developments
- 6.2 China Isotope & Radiation
- 6.2.1 China Isotope & Radiation Company Information
- 6.2.2 China Isotope & Radiation Business Overview
- 6.2.3 China Isotope & Radiation Nuclear Drug for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 China Isotope & Radiation Nuclear Drug for Therapeutic Product Portfolio
- 6.2.5 China Isotope & Radiation Recent Developments
- 6.3 Curium Pharmaceuticals
- 6.3.1 Curium Pharmaceuticals Company Information
- 6.3.2 Curium Pharmaceuticals Business Overview
- 6.3.3 Curium Pharmaceuticals Nuclear Drug for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Curium Pharmaceuticals Nuclear Drug for Therapeutic Product Portfolio
- 6.3.5 Curium Pharmaceuticals Recent Developments
- 6.4 Dongcheng
- 6.4.1 Dongcheng Company Information
- 6.4.2 Dongcheng Business Overview
- 6.4.3 Dongcheng Nuclear Drug for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Dongcheng Nuclear Drug for Therapeutic Product Portfolio
- 6.4.5 Dongcheng Recent Developments
- 6.5 International Isotopes
- 6.5.1 International Isotopes Company Information
- 6.5.2 International Isotopes Business Overview
- 6.5.3 International Isotopes Nuclear Drug for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 International Isotopes Nuclear Drug for Therapeutic Product Portfolio
- 6.5.5 International Isotopes Recent Developments
- 6.6 Jubilant Radiopharma
- 6.6.1 Jubilant Radiopharma Company Information
- 6.6.2 Jubilant Radiopharma Business Overview
- 6.6.3 Jubilant Radiopharma Nuclear Drug for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Jubilant Radiopharma Nuclear Drug for Therapeutic Product Portfolio
- 6.6.5 Jubilant Radiopharma Recent Developments
- 6.7 Lantheus
- 6.7.1 Lantheus Company Information
- 6.7.2 Lantheus Business Overview
- 6.7.3 Lantheus Nuclear Drug for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Lantheus Nuclear Drug for Therapeutic Product Portfolio
- 6.7.5 Lantheus Recent Developments
- 6.8 Mundipharma
- 6.8.1 Mundipharma Company Information
- 6.8.2 Mundipharma Business Overview
- 6.8.3 Mundipharma Nuclear Drug for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Mundipharma Nuclear Drug for Therapeutic Product Portfolio
- 6.8.5 Mundipharma Recent Developments
- 6.9 Q BioMed
- 6.9.1 Q BioMed Company Information
- 6.9.2 Q BioMed Business Overview
- 6.9.3 Q BioMed Nuclear Drug for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Q BioMed Nuclear Drug for Therapeutic Product Portfolio
- 6.9.5 Q BioMed Recent Developments
- 6.10 Bayer
- 6.10.1 Bayer Company Information
- 6.10.2 Bayer Business Overview
- 6.10.3 Bayer Nuclear Drug for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Bayer Nuclear Drug for Therapeutic Product Portfolio
- 6.10.5 Bayer Recent Developments
- 6.11 Novartis
- 6.11.1 Novartis Company Information
- 6.11.2 Novartis Business Overview
- 6.11.3 Novartis Nuclear Drug for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Novartis Nuclear Drug for Therapeutic Product Portfolio
- 6.11.5 Novartis Recent Developments
7 North America
- 7.1 North America Nuclear Drug for Therapeutic Market Size (2021-2032)
- 7.2 North America Nuclear Drug for Therapeutic Market Size by Type
- 7.2.1 North America Nuclear Drug for Therapeutic Market Size by Type (2021-2026)
- 7.2.2 North America Nuclear Drug for Therapeutic Market Size by Type (2027-2032)
- 7.2.3 North America Nuclear Drug for Therapeutic Market Share by Type (2021-2032)
- 7.3 North America Nuclear Drug for Therapeutic Market Size by Application
- 7.3.1 North America Nuclear Drug for Therapeutic Market Size by Application (2021-2026)
- 7.3.2 North America Nuclear Drug for Therapeutic Market Size by Application (2027-2032)
- 7.3.3 North America Nuclear Drug for Therapeutic Market Share by Application (2021-2032)
- 7.4 North America Nuclear Drug for Therapeutic Market Size by Country
- 7.4.1 North America Nuclear Drug for Therapeutic Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Nuclear Drug for Therapeutic Market Size by Country (2021-2026)
- 7.4.3 North America Nuclear Drug for Therapeutic Market Size by Country (2027-2032)
- 7.4.4 North America Nuclear Drug for Therapeutic Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Nuclear Drug for Therapeutic Market Size (2021-2032)
- 8.2 Europe Nuclear Drug for Therapeutic Market Size by Type
- 8.2.1 Europe Nuclear Drug for Therapeutic Market Size by Type (2021-2026)
- 8.2.2 Europe Nuclear Drug for Therapeutic Market Size by Type (2027-2032)
- 8.2.3 Europe Nuclear Drug for Therapeutic Market Share by Type (2021-2032)
- 8.3 Europe Nuclear Drug for Therapeutic Market Size by Application
- 8.3.1 Europe Nuclear Drug for Therapeutic Market Size by Application (2021-2026)
- 8.3.2 Europe Nuclear Drug for Therapeutic Market Size by Application (2027-2032)
- 8.3.3 Europe Nuclear Drug for Therapeutic Market Share by Application (2021-2032)
- 8.4 Europe Nuclear Drug for Therapeutic Market Size by Country
- 8.4.1 Europe Nuclear Drug for Therapeutic Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Nuclear Drug for Therapeutic Market Size by Country (2021-2026)
- 8.4.3 Europe Nuclear Drug for Therapeutic Market Size by Country (2027-2032)
- 8.4.4 Europe Nuclear Drug for Therapeutic Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Nuclear Drug for Therapeutic Market Size (2021-2032)
- 9.2 China Nuclear Drug for Therapeutic Market Size by Type
- 9.2.1 China Nuclear Drug for Therapeutic Market Size by Type (2021-2026)
- 9.2.2 China Nuclear Drug for Therapeutic Market Size by Type (2027-2032)
- 9.2.3 China Nuclear Drug for Therapeutic Market Share by Type (2021-2032)
- 9.3 China Nuclear Drug for Therapeutic Market Size by Application
- 9.3.1 China Nuclear Drug for Therapeutic Market Size by Application (2021-2026)
- 9.3.2 China Nuclear Drug for Therapeutic Market Size by Application (2027-2032)
- 9.3.3 China Nuclear Drug for Therapeutic Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Nuclear Drug for Therapeutic Market Size (2021-2032)
- 10.2 Asia Nuclear Drug for Therapeutic Market Size by Type
- 10.2.1 Asia Nuclear Drug for Therapeutic Market Size by Type (2021-2026)
- 10.2.2 Asia Nuclear Drug for Therapeutic Market Size by Type (2027-2032)
- 10.2.3 Asia Nuclear Drug for Therapeutic Market Share by Type (2021-2032)
- 10.3 Asia Nuclear Drug for Therapeutic Market Size by Application
- 10.3.1 Asia Nuclear Drug for Therapeutic Market Size by Application (2021-2026)
- 10.3.2 Asia Nuclear Drug for Therapeutic Market Size by Application (2027-2032)
- 10.3.3 Asia Nuclear Drug for Therapeutic Market Share by Application (2021-2032)
- 10.4 Asia Nuclear Drug for Therapeutic Market Size by Country
- 10.4.1 Asia Nuclear Drug for Therapeutic Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Nuclear Drug for Therapeutic Market Size by Country (2021-2026)
- 10.4.3 Asia Nuclear Drug for Therapeutic Market Size by Country (2027-2032)
- 10.4.4 Asia Nuclear Drug for Therapeutic Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Nuclear Drug for Therapeutic Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Nuclear Drug for Therapeutic Market Size by Type
- 11.2.1 South America, Middle East & Africa Nuclear Drug for Therapeutic Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Nuclear Drug for Therapeutic Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Nuclear Drug for Therapeutic Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Nuclear Drug for Therapeutic Market Size by Application
- 11.3.1 South America, Middle East & Africa Nuclear Drug for Therapeutic Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Nuclear Drug for Therapeutic Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Nuclear Drug for Therapeutic Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Nuclear Drug for Therapeutic Market Size by Country
- 11.4.1 South America, Middle East & Africa Nuclear Drug for Therapeutic Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Nuclear Drug for Therapeutic Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Nuclear Drug for Therapeutic Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Nuclear Drug for Therapeutic Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst